Polysubstituted indan-1-ol systems for the prophylaxis or treatment of obesity

US6812256B2 · kind B2 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Gerhard Jaehne · Frankfurt, DE
• Volker Krone · Flörsheim, DE
• Martin Bickel · Frankfurt am Main, DE
• Matthias Gossel · Frankfurt am Main, DE

Key dates

• Filing date: Oct 27, 2003
• Grant date: Nov 2, 2004
• Expiry date: Oct 27, 2023

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P9/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Polysubstituted indan-1-ol compounds of formula I, its physiologically acceptable salts and physiologically functional derivatives are disclosed Compositions comprising the same, methods of preparation and methods for the prophylaxis or treatment of obesity are also disclosed herein.